One stock that might be an intriguing choice for investors right now is Cogent Biosciences, Inc. (COGT) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably tak ...

Company Announcement - Cogent Biosciences, Inc. will participate in a fireside chat at the Leerink Healthcare Conference on March 12, 2025, at 10:00 a.m. ET [1] - A live webcast of the event will be available on the Investors & Media page of Cogent's website, with a replay accessible approximately two hours after the event and archived for up to 30 days [2] Inducement Grant - The Compensation Committee of Cogent's Board of Directors approved an "inducement" equity award for a new employee on March 4, 2025, under the company's 2020 Inducement Plan [3] - The award consists of a nonqualified option to purchase 90,000 shares of Cogent common stock, with a 10-year term and an exercise price equal to the closing price on the grant date [3] - The vesting schedule includes 25% vesting on the 1-year anniversary of the grant date, with the remainder vesting in equal monthly installments over the subsequent 36 months, contingent on the employee's continued employment [3] Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [4] - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing a portfolio of targeted therapies for mutations in ErbB2, PI3Kα, and KRAS [4] - Cogent is headquartered in Waltham, MA, and Boulder, CO, and provides updates and important information for investors on its website and social media platforms [4]

Core Insights - Cogent Biosciences announced expanded clinical results from the SUMMIT trial evaluating bezuclastinib for nonadvanced systemic mastocytosis, showing a 65% mean improvement in Total Symptom Score (TSS) at 48 weeks, with 88% of patients achieving at least a 50% reduction in TSS [1][6] Group 1: Clinical Trial Results - The SUMMIT trial is a registration-directed, randomized, double-blind, placebo-controlled study involving patients with nonadvanced systemic mastocytosis, with results focusing on those who received 100 mg bezuclastinib for at least 48 weeks [3] - Updated clinical data indicate a 63% reduction from baseline in the most severe symptom at 48 weeks, and quality of life improved to mild as early as week four, sustained through 48 weeks as measured by the Mastocytosis Quality-of-Life scale [6] Group 2: Safety and Patient Outcomes - The median duration of bezuclastinib treatment was 56 weeks for active patients and 40 weeks for placebo patients who crossed over to the Open Label Extension [4] - Most treatment-emergent adverse events were low grade and reversible, with common events including hair discoloration and transaminase elevations, all of which were asymptomatic and reversible [4] Group 3: Future Plans - Top-line results from SUMMIT Part 2 are expected in July 2025, with the company aiming to make bezuclastinib available to all nonadvanced systemic mastocytosis patients as quickly as possible [2][8]

OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38443 COGENT BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Exhibit 99.1 https://files.reportify.cc/m Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 Bezuclastinib – Gastrointestinal Stromal Tumors (GIST) • Report top-line results by the end of 2025 from the pivotal Phase 3 PEAK trial. PEAK is a global, blinded, randomized clinical trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in patients with ...

• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2nd-line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biot ...

Group 1 - Cogent Biosciences, Inc. (COGT) is a notable stock in the Medical sector, currently ranked 2 in the Zacks Sector Rank, which evaluates the average Zacks Rank of individual stocks within the sector [2][3] - The Zacks Consensus Estimate for COGT's full-year earnings has increased by 2.6% over the past quarter, indicating a positive trend in analyst sentiment and earnings outlook [4] - COGT has achieved a year-to-date performance increase of approximately 12.3%, significantly outperforming the average gain of 5.3% in the Medical sector [4] Group 2 - Cogent Biosciences, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 510 companies and is currently ranked 65 in the Zacks Industry Rank [6] - Stocks in the Medical - Biomedical and Genetics industry have gained about 2.9% year-to-date, showcasing COGT's superior performance within this group [6] - Another outperforming stock in the Medical sector is Cardiol Therapeutics Inc. (CRDL), which has increased by 7% year-to-date, with a consensus EPS estimate rise of 12.5% over the past three months [5][7]

Core Insights - Cogent Biosciences, Inc. is set to present a poster on bezuclastinib at the 2025 AAAAI Annual Meeting, focusing on its efficacy and safety in patients with Non-Advanced Systemic Mastocytosis [1][3] Company Overview - Cogent Biosciences specializes in developing precision therapies for genetically defined diseases, with bezuclastinib being its most advanced clinical program [4] - Bezuclastinib is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is linked to systemic mastocytosis and other cancers [4] - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [4] Presentation Details - The poster presentation titled "Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial" will take place on March 1, 2025 [3] - The session will highlight the benefits of long-term use of 100mg bezuclastinib over at least 48 weeks [2] - The presentation is scheduled for 9:45am – 10:45am PT at the San Diego Convention Center [3]

Cogent Biosciences Inc (COGT) Conference Summary Company Overview - Cogent Biosciences is focused on developing small molecule targeted agents for rare genetically driven diseases, with its lead asset being bezuclasanib, a selective KIT mutant inhibitor [5][4]. Key Points on Bezuclasanib - Bezuclasanib is currently in three pivotal studies set to read out in 2025: - SUMMIT study for non-advanced systemic mastocytosis (July 2025) - APEC study for advanced systemic mastocytosis (second half of 2025) - PEAK trial for gastrointestinal stromal tumor patients (end of 2025) [5][6]. - Bezuclasanib is differentiated from other KIT inhibitors, particularly Avapritinib, in two main ways: - It is about 10 times more selective for mutant KIT over wild type and does not target other kinases, reducing tolerability challenges [9][10]. - It has minimal penetration into CNS tissue, avoiding cognitive issues associated with other drugs [10][11]. Market Opportunity - The non-advanced systemic mastocytosis market is estimated to be a $4 billion total available market, with bezuclasanib expected to address unmet needs for symptomatic control [14][12]. - Blueprint's Avapritinib achieved approximately $500 million in first-year sales, indicating strong demand for treatments in this space [13][14]. Clinical Data and Safety Profile - Phase one data showed a nearly 56% improvement in total symptom score reduction at 24 weeks, with almost 90% of patients achieving at least a 50% improvement [17][18]. - Bezuclasanib has a benign safety profile, with reversible and asymptomatic transaminase elevations being the primary concern, unlike Avapritinib, which has reported neuropsychiatric events and fatalities associated with cerebral hemorrhage [22][24][25][26]. Formulation and Development - The formulation of bezuclasanib was changed to reduce pill burden and improve bioavailability, with no risk in translating Phase one data to pivotal studies [27][28]. - SUMMIT PART two is designed similarly to the PIONEER study, allowing patients who have previously been treated with Avapritinib [31][32]. Advanced Systemic Mastocytosis (ASM) and GIST Opportunities - The ASM population represents about 10% of the total mastocytosis market, estimated at $300 million to $400 million [38]. - In GIST treatment, bezuclasanib is expected to provide coverage for all known resistance mutations when combined with SUTENT, potentially leading to longer progression-free survival [41][43]. Conclusion - The upcoming pivotal trial readouts in 2025 are critical for Cogent Biosciences, with bezuclasanib positioned as a promising treatment option in the rare disease market, particularly for systemic mastocytosis and gastrointestinal stromal tumors [5][6][48].

Core Insights - Cogent Biosciences, Inc. is participating in the Guggenheim SMID Cap Biotech Conference on February 5, 2025, at 9:30 a.m. ET [1] - The company focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor [3] Company Overview - Cogent Biosciences is based in Waltham, MA, and Boulder, CO, and is dedicated to creating targeted therapies for serious diseases driven by genetic mutations [3] - The company is currently conducting a Phase 1 study of a novel FGFR2 inhibitor and is developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [3] Event Information - A live webcast of the conference participation can be accessed on Cogent's Investors & Media page, with a replay available for 30 days post-event [2]